TY - JOUR T1 - In hypertensive patients with elevated risk of cardiovascular disease, targeting systolic blood pressure to less than 120 mm Hg significantly reduces the rate of fatal and non-fatal cardiovascular events as well as death from any cause JF - Evidence Based Medicine JO - Evid Based Med SP - 101 LP - 101 DO - 10.1136/ebmed-2016-110397 VL - 21 IS - 3 AU - Mina Owlia AU - Sripal Bangalore Y1 - 2016/06/01 UR - http://ebm.bmj.com/content/21/3/101.abstract N2 - Commentary on: Wright JT Jr., Williamson JD, Whelton PK, et al., SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–16.OpenUrlCrossRefPubMedHypertension is among the most significant modifiable risk factor for cardiovascular disease, yet there is considerable debate on the optimal blood pressure (BP) goal. Observational studies1 and the ACCORD trial2 suggest a target organ heterogeneity in that with lower systolic BP goals (<120 mm Hg) the risk of cerebrovascular events are reduced, but not coronary events. As such, systolic BP goals of <130, <140 or <150 mm Hg, have been proposed in the last decade by hypertension guideline societies.3 ,4SPRINT was a randomised, controlled, open-label trial of targeted BP treatment to the standard BP goal (<140 mm Hg) compared … ER -